Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gefurulimab (Primary)
Indications Myasthenia gravis
Focus Registrational; Therapeutic Use
Acronyms PREVAIL
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

24 Jul 2025 Primary endpoint(Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26) has been met.
24 Jul 2025 Results presented in the AstraZeneca media release.
21 Jun 2025 According to AstraZeneca media release, company will present data from this study in an ePoster presentation at the European Academy of Neurology (EAN) Annual Congress in Helsinki, Finland, 21 to 24 June 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com